What Researchers Did
Researchers assessed whether a modified low-dose HBOT protocol (originally designed during COVID-19 capacity constraints) could effectively treat radiation cystitis and proctitis after pelvic cancer radiotherapy.
What They Found
The modified protocol achieved clinical outcomes comparable to standard HBOT in prior studies, with significant improvements in urinary and bowel symptoms. Patients tolerated the adjusted regimen well, with minimal adverse effects reported.
What This Means for Canadian Patients
Radiation cystitis and proctitis are recognized OHIP-covered indications for HBOT in Ontario. This study suggests that protocol flexibility does not compromise outcomes, which is relevant for Canadian centres managing chamber capacity.
Canadian Relevance
Covers an OHIP-covered indication: delayed radiation injury (radiation cystitis and proctitis). Ontario patients with these complications following pelvic radiotherapy may be eligible for publicly funded HBOT.
Study Limitations
Protocol modifications and small sample sizes limit direct comparison with standard regimens.